Abstract

BackgroundPeripheral blood interferon-gamma release assays (IGRAs) have sub-optimal sensitivity and specificity for diagnosis of active pulmonary tuberculosis (TB). However, assessment of local immune responses has been reported to improve the accuracy of TB diagnosis.MethodsWe enrolled HIV-infected adults with cough ≥2 weeks’ duration admitted to Mulago Hospital in Kampala, Uganda and referred for bronchoscopy following two negative sputum acid-fast bacillus smears. We performed an ELISPOT-based IGRA (T-SPOT.TB®, Oxford Immunotec, Oxford, UK) using peripheral blood and bronchoalveolar lavage (BAL) fluid mononuclear cells, and determined the accuracy of IGRAs using mycobacterial culture results as a reference standard.Results94 HIV-infected patients with paired peripheral blood and BAL IGRA results were included. The study population was young (median age 34 years [IQR 28–40 years]) and had advanced HIV/AIDS (median CD4+ T-lymphocyte count 60 cells/µl [IQR 22–200 cells/µl]). The proportion of indeterminate IGRA results was higher in BAL fluid than in peripheral blood specimens (34% vs. 14%, difference 20%, 95% CI 7–33%, p = 0.002). BAL IGRA had moderate sensitivity (73%, 95% CI 50–89%) but poor specificity (48%, 95% CI 32–64%) for TB diagnosis. Sensitivity was similar (75%, 95% CI 57–89%) and specificity was higher (78%, 95% CI 63–88%) when IGRA was performed on peripheral blood.ConclusionsBAL IGRA performed poorly for the diagnosis of smear-negative TB in a high HIV/TB burden setting. Further studies are needed to examine reasons for the large proportion of indeterminate results and low specificity of BAL IGRA for active TB in high HIV/TB burden settings.

Highlights

  • Interferon-gamma release assays (IGRAs) are being used increasingly for the detection of Mycobacterium tuberculosis (MTB) infection

  • TB-specific antigens (ESAT-6 and CFP-10) have been detected at 10- to 100fold higher frequency in bronchoalveolar lavage (BAL) fluid compared to peripheral blood specimens in patients with pulmonary TB [5,6], which may enhance the sensitivity of interferon-gamma release assays (IGRAs)

  • There were no differences in gender, age, CD4+ T-lymphocyte count, anti-retroviral use, or in-hospital mortality in patients with and without indeterminate BAL IGRAs (p.0.2 for all comparisons)

Read more

Summary

Introduction

Interferon-gamma release assays (IGRAs) are being used increasingly for the detection of Mycobacterium tuberculosis (MTB) infection. Commercial ELISA- and ELISPOT-based assays that detect interferon-gamma release following overnight stimulation with MTB-specific antigens (Early Secreted Antigen Target-6 [ESAT-6] and Culture Filtrate Protein-10 [CFP-10]) are recommended as an alternative to the tuberculin skin test for targeted testing of individuals for latent tuberculosis (TB) infection. Assessing MTB-specific immune responses at the site of disease (i.e., the lungs) may improve IGRA performance for diagnosis of active pulmonary TB. Peripheral blood interferon-gamma release assays (IGRAs) have sub-optimal sensitivity and specificity for diagnosis of active pulmonary tuberculosis (TB). Assessment of local immune responses has been reported to improve the accuracy of TB diagnosis

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.